Orebro University

OXFORD, England, Feb. 27, 2025 /PRNewswire/ -- Brainomix, a pioneer in stroke AI imaging software and European market leader, has announced a strategic partnership with Medtronic Neurovascular, a global leader in medical technology. The collaboration aims to enhance stroke care for patients across Western Europe by integrating cutting-edge artificial intelligence (AI) solutions into clinical practice, expanding access to life-changing treatments and improving patient outcomes. The Brainomix 360 Stroke platform is powered by state-of-the-art AI algorithms that provide real-time interpretation of brain scans to aid treatment and transfer decisions for stroke patients. Brainomix 360 Stroke was studied in the largest real-world evaluation of stroke AI – involving data from more than 450,000 patients across England over a 5-year period – with results showing a doubling of thrombectomy rates in Brainomix sites, and an additional 37% increase compared with non-evaluation sites. By combining Brainomix's AI-powered imaging technology with Medtronic's expertise in neurovascular treatments, the partnership represents a significant step forward in stroke care. The collaboration will support faster, more accurate diagnoses, enabling healthcare professionals across the region to make better-informed decisions and deliver life-saving interventions more efficiently Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, underscored the shared vision of both companies: "This partnership with Medtronic is a natural fit, with the leading neurovascular device provider joining forces with the leading stroke AI imaging partner, both aligned around a mutual commitment towards improving stroke care for all patients. We have demonstrated that our software impacts treatment rates, and working with Medtronic, we now have an opportunity together to deliver a solution for stroke networks across Europe that will enable more patients to get access to vital stroke treatments. Dr. Alex Solich, Senior Consultant for Neurointervention at Karolinska University Hospital & Örebro Hospital, emphasized the impact this partnership will have on patient outcomes: "As a stroke physician, I see firsthand the critical importance of speed and precision in delivering life-saving treatment. That's why I'm genuinely excited about the partnership between Medtronic Neurovascular and Brainomix. Combining Medtronic's proven neurovascular technologies with Brainomix's AI-driven imaging has the potential to make a real difference—not just in streamlining workflows, but in giving patients a better chance at recovery. Knowing that we are moving toward more efficient, data-driven decision-making gives me great confidence that we can continue to push the boundaries of stroke care and improve outcomes for countless patients." Key Benefits of the Partnership Transforming Treatment Regionally: Medtronic's established presence in Western Europe will accelerate the adoption of Brainomix's AI technology, ensuring that life-saving innovations reach more hospitals and healthcare providers across the region. Enhanced Diagnostic Accuracy: Integrating Brainomix's AI-powered imaging software with Medtronic's neurovascular solutions will provide healthcare professionals with highly precise diagnostic tools, enabling quicker and more informed decisions crucial for timely stroke treatment. Optimized Clinical Workflows: By simplifying and accelerating stroke detection and intervention, this partnership will help alleviate the burden on healthcare providers and enhance efficiency across hospital networks. About Brainomix Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients. To learn more about Brainomix and its technology visit , and follow us on Twitter, LinkedIn and Facebook. Contacts Jeff Wyrtzen, Chief Marketing & Business Development Officer [email protected] M +44 (0)7927 164210 T +44 (0)1865 582730 Media Enquiries Charles Consultants Sue Charles [email protected] M +44 (0)7968 726585 Logo - SOURCE Brainomix WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

MONDAY, July 29, 2024 -- For patients with major depressive disorder (MDD), seizure duration of 60 to 69 seconds induced by electroconvulsive therapy (ECT) is associated with the highest remission rates compared with seizure duration of less than 20 seconds, according to a study published online July 25 in JAMA Network Open . Cecilia Gillving, from the University Health Care Research Centre at Örebro University in Sweden, and colleagues conducted a population-based cohort study using data from the Swedish National Quality Register for ECT to examine the association between seizure duration, potential confounding variables, and ECT treatment outcome. A total of 6,998 patients with unipolar MDD treated with unilateral electrode placement were included. The analysis used electroencephalographic (EEG) seizure duration from the first ECT treatment session for each patient. The researchers found that 39.3 percent of patients achieved remission after ECT. The highest remission rates were seen for patients with EEG seizure duration of 60 to 69 seconds compared with those with seizure duration of less than 20 seconds (odds ratio, 2.17). Associations were seen for anticonvulsant medications with shorter seizure duration and lower remission rates (e.g., lamotrigine: β coefficient, −6.02; adjusted odds ratio, 0.67). "This cohort study is the largest yet supporting the association between seizure length and remission from MDD after ECT," the authors write. "Seizure duration appeared to be indicative of adequate treatment quality." Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

LUND, SE / ACCESSWIRE / November 24, 2023 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data providing further support for its lead assets, the IL1RAP-binding antibodies nadunolimab (CAN04) and CAN10, in both cancer and cardiovascular disease. The data shows that IL1RAP blockade results in reduced vascular inflammation and that levels of IL1RAP correlate with various inflammatory markers in inflamed tissue. Vascular inflammation is considered integral for both cardiovascular disease and tumor growth. The findings demonstrate that antibody blockade of IL1RAP in a cell-based system results in decreased levels of multiple inflammatory markers, including interleukin-6 (IL-6), produced by vascular cells. The data further indicates that these effects may lead to reduced recruitment of inflammatory immune cells. Notably, analyses of human atherosclerotic plaques show that the level of IL1RAP correlated with several of the inflammatory markers reduced by IL1RAP blockade, including IL-6. "The new results presented today add further support for the potential of both nadunolimab and CAN10 in treatment of life-threatening diseases and provide useful information for future biomarker strategies," said Göran Forsberg, CEO of Cantargia. These data were generated by Ass. Prof. Karin Franzén's research group at Örebro University and are today presented in a poster session at the Chemical Biology Workshop: Drug & Biomarker Discovery in Athens. The poster is now also available at Cantargia's webpage (link). About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . About nadunolimab (CAN04) The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316, evaluates nadunolimab in combination with standard chemotherapies in patients with PDAC (gemcitabine/nab-paclitaxel) or NSCLC (platinum-based chemotherapies). Positive interim data show durable responses for the combination therapy in 73 PDAC patients, resulting in median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 30 NSCLC patients with median PFS of 7.0 months and a response rate of 53%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase Ib/II trial TRIFOUR, NCT05181462, also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin/gemcitabine. Nadunolimab is also investigated with chemotherapy in the clinical trials CAPAFOUR, NCT04990037, and CESTAFOUR, NCT05116891, and with the checkpoint inhibitor pembrolizumab in the CIRIFOUR trial, NCT04452214. About CAN10 The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. Inhibition of these signals can be of significant value in the treatment of several inflammatory or autoimmune diseases. The initial focus of CAN10 will be on two severe diseases: myocarditis and systemic sclerosis. In preclinical in vivo models of myocarditis, a CAN10 surrogate antibody significantly reduced the development of inflammation and fibrosis, and significantly counteracted the deterioration of the cardiac function. The CAN10 surrogate also inhibited disease development in models of systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis and peritonitis. CAN10 is currently evaluated in a phase I clinical trial, with initial data expected in 2024. Attachments Cantargia reports new preclinical data confirming the potential of nadunolimab and CAN10 SOURCE: Cantargia View source version on accesswire.com: